We can’t show the full text here under this license. Use the link below to read it at the source.
Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes
Tirzepatide: A new once-weekly drug that activates two hormones to treat type 2 diabetes
AI simplified
Abstract
The SURPASS phase III clinical trials for tirzepatide involved over 13,000 patients with type 2 diabetes mellitus.
- Gastrointestinal hormones, including incretins, are used to manage type 2 diabetes.
- has recently shown significant effects on insulin and glucagon secretion under normal blood sugar conditions.
- The combination of GIP and signaling may enhance therapeutic effects compared to GLP-1 alone.
- Tirzepatide is being developed as a dual agonist targeting both GIP and GLP-1 receptors.
- The anticipated clinical availability of tirzepatide could offer new understanding of diabetes and GIP's role in its development.
AI simplified
Key numbers
90%
HbA1c Achievement Rate
Patients achieving HbA1c levels <7% in SURPASS trials.
6.2–12.9 kg
Weight Reduction
Weight reduction range depending on tirzepatide dosage.
13–27%
Weight Loss Rate
Patients losing 15% or more of body weight.